Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
9 clinical trials · Condition
◉ Watch Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
| Record | Firm | Date |
|---|---|---|
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782) | Northwestern University | 2022-03-21 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971) | Fred Hutchinson Cancer Center | 2017-11-03 |
| JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02706405) | Fred Hutchinson Cancer Center | 2016-11-15 |
Track Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements automatically
Every clearance here is in the API, with alerts when new ones post.